Mauro M.
- Country
- Italy
- Department
- Gastroenterology
Research Overview
- A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis
- A Study to Test How Well Obefazimod Works and How Safe It Is for Patients with Moderately to Severely Active Ulcerative Colitis
- Long‑Term Safety and Efficacy of SPY001‑001 Monotherapy and Combination Therapy with Long‑Acting Antibodies in Adults with Ulcerative Colitis
Data & Insights
Has run more than one trial at 196 of 378 partner sites.
Specializations
Inflammatory Bowel Disease Management
The investigator specializes in treating inflammatory bowel disease, with particular emphasis on both ulcerative colitis and Crohn's disease in their moderate to severe forms.
- Advanced therapeutic approaches for ulcerative colitis
- Novel treatment strategies for Crohn's disease
- Long-term disease management protocols
Their research encompasses innovative therapeutic interventions for patients with treatment-resistant conditions.
Clinical Innovation
The investigator focuses on evaluating biological therapies and novel compounds for gastrointestinal disorders, including comparative studies of emerging treatments.
- Biosimilar evaluation studies
- Combination therapy approaches
- Maintenance treatment strategies
Their work includes assessment of both established and experimental therapeutic agents for inflammatory conditions.
Post-Surgical Care
The investigator has expertise in post-operative disease management, particularly focusing on preventing recurrence in Crohn's disease patients after surgical intervention.
- Post-surgical recurrence prevention
- Endoscopic monitoring protocols
- Risk factor assessment
Their research includes development of targeted approaches for patients requiring surgical intervention.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.